OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Welslau on the Interim Results of the REFLECT Trial in DLBCL

August 25th 2020

Manfred Welslau, MD, discusses the interim results of the REFLECT trial in diffuse large B-cell lymphoma.

Dr. Shum on Emerging Targeted Therapies in EGFR-Mutant NSCLC

August 25th 2020

Elaine Shum, MD, discusses emerging targeted therapies in EGFR-mutant non–small cell lung cancer.

Dr. McGregor on the Evolving Treatment Landscape of RCC

August 25th 2020

Bradley McGregor, MD, discusses the evolving treatment landscape of renal cell carcinoma.

Dr. Schenk on the Evolving Treatment Landscape in Lung Cancer

August 25th 2020

Erin Schenk, MD, PhD, discusses the rapidly evolving treatment landscape in lung cancer.

Dr. Partridge on the Role of Genomic Testing in Breast Cancer

August 25th 2020

Ann H. Partridge, MD, MPH, discusses the role of genomic testing in breast cancer.

Dr. Hamid on TMB as a Biomarker for Immunotherapy Response in Melanoma

August 24th 2020

Omid Hamid, MD, discusses the utility of tumor mutational burden as a biomarker for response to immunotherapy in patients with melanoma.

Dr. Pautier on Doxorubicin Plus Trabectedin in Soft Tissue Sarcoma

August 24th 2020

Patricia Pautier, MD, discusses the toxicity profile of doxorubicin with trabectedin in the phase 2 LMS-02 trial in patients with metastatic/advanced uterine and soft tissue leiomyosarcoma.

Dr. Sabari on Novel Immunotherapy Combos Under Investigation in NSCLC

August 24th 2020

Joshua K. Sabari, MD, discusses novel immunotherapy combinations that are under investigation in non–small cell lung cancer.

Dr. Sonpavde on the Need for Phase 3 Data With Pembrolizumab or Atezolizumab in Bladder Cancer

August 24th 2020

Guru P. Sonpavde, MD, discusses the need for phase 3 data evaluating frontline pembrolizumab or atezolizumab in bladder cancer.

Dr. Leslie on Frontline Treatment Options in Follicular Lymphoma

August 24th 2020

Lori A. Leslie, MD, lymphoma attending, discusses frontline treatment options in follicular lymphoma.

Dr. Mamounas on the Role of Extended Adjuvant Endocrine Therapy in ER+ Breast Cancer

August 24th 2020

Eleftherios (Terry) P. Mamounas, MD, MPH, FACS, discusses the role of extended adjuvant endocrine receptor–positive breast cancer.

Dr. Saba on Scheduling Challenges With Cisplatin in Head and Neck Cancer

August 24th 2020

Nabil F. Saba, MD, FACP, discusses scheduling challenges with cisplatin in head and neck cancer.

Dr. Chang on the Impact of COVID-19 on the Surgical Management of GU Cancers

August 24th 2020

Steven Lee Chang, MD, discusses the impact of the coronavirus disease 2019 on the surgical management of patients with genitourinary cancers.

Dr. Leslie on Phase 1b Trial of Tazemetostat Plus Lenalidomide/Rituximab in Follicular Lymphoma

August 22nd 2020

Lori A. Leslie, MD, discusses a phase 1b study with tazemetostat plus lenalidomide and rituximab in patients with follicular lymphoma.

Dr. Skarbnik on Active Surveillance in Follicular Lymphoma

August 22nd 2020

Alan P. Z. Skarbnik, MD, discusses the watch-and-wait approach in patients with follicular lymphoma.

Dr. Burke on Tazemetostat’s Mechanism of Action in EZH2-Mutated Follicular Lymphoma

August 22nd 2020

John M. Burke, MD, discusses the role of tazemetostat in EZH2-mutated follicular lymphoma.

Dr. Reid on Remaining Challenges Regarding the Management of Immune-Related AEs

August 21st 2020

Pankti Reid, MD, MPH, discusses remaining challenges regarding the management of immune-related adverse effects.

Dr. Garon on Unique Challenges of COVID-19 in Lung Cancer

August 21st 2020

Edward B. Garon, MD, discusses unique challenges of the coronavirus disease 2019 in lung cancer.

Dr. Garon on the Expanding Treatment Landscape in Lung Cancer

August 21st 2020

Edward B. Garon, MD, discusses the expanding treatment landscape in lung cancer.

Dr. Chu on the Impact of the KEYNOTE-177 Trial in mCRC

August 21st 2020

Edward Chu, MD, MMS, discusses the impact of the phase 3 MK-3475-177/KEYNOTE-177 trial in metastatic colorectal cancer.